Moderna (MRNA) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

The observation that mRNA vaccines can sensitize tumors to immunotherapy has researchers eager to test how mRNA’s ability to activate the immune system could be harnessed in oncology.

Scientists have developed an experimental mRNA vaccine that, when combined with existing immunotherapy drugs, could 'teach' the immune system to recog ...

Lung and skin cancer patients who were taking "checkpoint inhibitors" and had the COVID vaccine saw surprising results.

A presentation by scientists on a work group for the Centers for Disease Control and Prevention’s vaccine advisory panel ...

The decades-long quest to harness the power of messenger RNA to enhance cancer treatment has focused primarily on its value ...

All of these questions deserve urgent exploration. Unfortunately, the discovery comes at a particularly difficult moment for ...

For the quarter ended September 2025, Moderna (MRNA) reported revenue of $1.02 billion, down 45.4% over the same period last year. EPS came in at -$0.51, compared to $0.03 in the year-ago quarter. The ...

President Donald Trump’s physician, Dr. Sean P. Barbabella, announced that after conducting a battery of tests, he found that ...

The study, published in the journal Nature, showed the jabs provided an immunity boost that helped extend survival for ...

Vaccines that resemble viruses generally produce a stronger immune response, while mRNA versions are much quicker and cheaper to make. Now we are getting the best of both worlds, in the form of mRNA ...